IL-33/ST2信号通路在肾脏疾病中作用机制的研究进展

doi:10.12092/j.issn.1009-2501.2025.08.014

中国临床药理学与治疗学 ›› 2025, Vol. 30 ›› Issue (8): 1122-1126.doi: 10.12092/j.issn.1009-2501.2025.08.014

IL-33/ST2信号通路在肾脏疾病中作用机制的研究进展

王倩^1,2,3, 梁昌昌^1,2,3, 沈士朋^1,2,3, 刘茂东^1,2,3, 白璐^1,2,3

¹河北医科大学第三医院肾内科;
²河北省糖尿病肾脏疾病重点实验室;
³河北省肾脏病研究中心; 石家庄 050011,河北

收稿日期:2024-10-11 修回日期:2024-12-24 出版日期:2025-08-26 发布日期:2025-08-12
通讯作者: 白璐,男,博士,副主任医师,研究方向：肾脏病的基础及临床研究。E-mail： bailu2011@126.com
作者简介:王倩,女,主治医师,研究方向：肾脏病的研究。
基金资助:
河北省中医药管理局科研计划项目（2022408）

Research progress on the mechanism of IL-33/ST2 signaling pathway in kidney diseases

WANG Qian, LIANG Changchang, SHEN Shipeng, LIU Maodong, BAI Lu

¹Department of Nephrology, the Third Hospital of Hebei Medical University;
²Hebei Key Laboratory for Diabetic Kidney Disease;
³Kidney Disease Research Center of Hebei Province, Shijiazhuang 050051, Hebei, China

Received:2024-10-11 Revised:2024-12-24 Online:2025-08-26 Published:2025-08-12

摘要/Abstract

摘要： 白介素-33（interleukin-33,IL-33）是白介素-1的超家族成员,是机体炎症的“预警因子”,当细胞坏死或组织损伤时,IL-33被大量释放,与其受体ST2结合形成复合体从而发挥多种生物学效应。在急性肾损伤、梗阻性肾病、糖尿病肾病、IgA肾病、狼疮性肾炎、移植肾等多种肾脏疾病中IL-33/ST2信号通路被激活,通过调节肾脏固有免疫和适应性免疫反应,在炎症及肾脏纤维化中发挥重要作用。本文综述了IL-33/ST2信号在常见肾脏疾病中的研究进展,希望为肾脏疾病的治疗提供新的靶点和思路。

关键词: 白介素-33, ST2, 免疫调节, 炎症, 肾脏疾病

Abstract: Interleukin-33 (IL-33) is a member of the interleukin-1 superfamily and a "warning factor" for inflammation in the body. When cells die or tissues are damaged, IL-33 is released in large quantities and binds to its receptor ST2 to form a complex, exerting various biological effects. IL-33/ST2 signaling pathway is activated in many kidney diseases, such as acute renal injury, obstructive nephropathy, diabetes nephropathy, IgA nephropathy, lupus nephritis, and kidney transplantation. It plays an important role in inflammation and renal fibrosis by regulating the intrinsic and adaptive immune responses of the kidney. This article reviews the research progress of IL-33/ST2 signaling in common kidney diseases, hoping to provide new targets and ideas for the treatment of kidney diseases.

Key words: interleukin-33, ST2, immune regulation, inflammation, kidney diseases

中图分类号:

王倩, 梁昌昌, 沈士朋, 刘茂东, 白璐. IL-33/ST2信号通路在肾脏疾病中作用机制的研究进展[J]. 中国临床药理学与治疗学, 2025, 30(8): 1122-1126.

WANG Qian^{1, 2, 3}, LIANG Changchang^{1, 2, 3}, SHEN Shipeng^{1, 2, 3}, LIU Maodong^{1, 2, 3}, BAI Lu^{1, 2, 3}. Research progress on the mechanism of IL-33/ST2 signaling pathway in kidney diseases[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(8): 1122-1126.

参考文献 33

[1]	杨卜嘉,于传飞,侯书婷, 等. IL-33/ST2信号通路及相关药物研究进展[J]. 中国药事, 2024, 38(1): 96-104.
[2]	杨谦, 吴云. IL-33/ST2在冠心病中的研究进展[J]. 内蒙古医学杂志, 2023, 55(8): 963-966.
[3]	赵文静, 陆爽. IL-33及ST2与纤维化疾病的研究进展[J]. 贵州医药, 2017, 41(9): 999-1001.
[4]	Cayrol C, Girard JP.IL-33: An alarmin cytokine with crucial roles in innate immunity, inflammation and allergy[J]. Curr Opin Immunol, 2014, 31: 31-37.
[5]	Cayrol C, Girard JP.Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family[J]. Immunol Rev, 2018, 281: 154-168.
[6]	Baekkevold ES, Roussigne M, Yamanaka T, et al.Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules[J]. Am J Pathol, 2003, 163: 69-79.
[7]	Schmitz J, Owyang A, Oldham E, et al.IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines[J]. Immunity, 2005, 23: 479-490.
[8]	信秀明, 刘鹏涛, 别自东. ST2与心力衰竭的研究进展[J]. 实用医技杂志, 2015, 9(3): 273-275.
[9]	Liu X, Hammel M, He Y, et al.Structural insights into the interaction of IL-33 with its receptors[J]. Proc Natl Acad Sci USA, 2013, 110(37): 14918-14923.
[10]	中国急性肾损伤临床实践指南专家组. 中国急性肾损伤临床实践指南[J]. 中华医学杂志, 2023, 103(42): 3332-3366.
[11]	Xu X, Nie S, Liu Z, et al.Epidemiology and clinical correlates of AKI in Chinese hospitalized adults[J]. Clin J Am Soc Nephrol, 2015, 10(9): 1510-1518.
[12]	Cheng X, Wu B, Liu Y, et al.Incidence and diagnosis of acute kidney injury in hospitalized adult patients: a retrospective observational study in a tertiary teaching hospital in Southeast China[J]. BMC Nephrol, 2017, 18(1): 203.
[13]	雷莹, 聂晟, 孙丹华, 等. 中国危重症住院患者急性肾损伤的流行病学分析[J]. 南方医科大学学报, 2016, 36(6): 744-750.
[14]	Akcay A, Nguyen Q, He Z, et al.IL-33 exacerbates acute kidney injury[J]. J Am Soc Nephrol, 2011, 22(11): 2057-2067.
[15]	Lee SJ, Borsting E, Declèves AE, et al.Podocytes express IL-6 and lipocalin 2/neutrophil gelatinase-associated lipocalin in lipopolysaccharide-induced acute glomerular injury[J]. Nephron Exp Nephrol, 2012, 121(3/4): e86-e96.
[16]	黄世雪, 杨定平. 肾缺血-再灌注损伤的致病机制及治疗方法的研究进展[J]. 临床肾脏病杂志 , 2019,19(7): 529-533.
[17]	Ferhat M, Robin A, Giraud S, et al.Endogenous IL-33 contributes to kidney ischemia reperfusion injury as an alarmin[J]. J Am Soc Nephrol, 2018, 29: 1-17.
[18]	Chen WY, Yang JL, Wu YH, et al.IL-33/ST2 axis mediates hyperplasia of intrarenal urothelium in obstructive renal injury[J]. Exp Mol Med, 2018, 50: 36.
[19]	Chen WY, Chang YJ, Su CH, et al.Upregulation of interleukin-33 in obstructive renal injury[J]. Biochem Biophys Res Commun, 2016, 473(3): 1026-1032.
[20]	Matoba K, Takeda Y, Nagai Y, et al.Unraveling the role of inflammation in the pathogenesis of diabetic kidney disease[J]. Int J Mol Sci, 2019, 20(14): 3393.
[21]	朱子璇. 白介素33在糖尿病肾病慢性病程中的免疫调节作用 [D]. 北京:北京协和医学院, 2021.
[22]	Liu T, Jin YQ, Wang Q, et al.IL-33/ST2L signaling alleviates diabetic nephropathy by regulating endoplasmic reticulum stress and apoptosis[J]. BMC Nephrol, 2023, 24(1): 361.
[23]	Zhang L, Niu JS, Zhang XM, et al.Metformin alleviates diabetic nephropathy through reducing serum Hcy and IL-33[J]. Open Med (Wars), 2019, 14: 625-628.
[24]	Zhang ZH, Wang HF, Zhang L, et al.Serum soluble ST2 and IL-10 levels correlate with IgA nephropathy severity[J]. J Immunol Res, 2016: 6540937.
[25]	郑维, 吕杨, 耿晓东, 等. IgA肾病患者肾脏组织中差异细胞因子的探索研究[J]. 中华肾病研究电子杂志, 2018, 7(3): 97-101.
[26]	何萌, 席艺华, 张晓磊, 等. IgA肾病患者尿液IL-6、IL-8、IL-33和MMP-9水平及其预测疾病进展的价值[J]. 中国医师杂志, 2022, 24(12): 1852-1856.
[27]	张辉, 杨念生, 鲁静, 等. 狼疮肾炎诊疗规范[J]. 中华内科杂志, 2021, 60(9): 784-790.
[28]	Ma Q, Xu MY, Jing X, et al.Honokiol suppresses renal macrophage-tubular epithelial cell interactions in lupus nephritis via NLRP3/IL-33/ST2 axis[J]. Cell Death Dis, 2023, 14(3): 174.
[29]	Li P, Wei L, Zheng XX.IL-33 neutralization ameliorates lupus in lupus-prone mice[J]. Inflammation, 2014, 37(3): 824-832.
[30]	Zhang J, Wang Z, Xu Z, et al.The potential role of IL-33 in renal transplant recipients with chronic allograft dysfunction[J]. Ann Transplant, 2016, 21: 611-618.
[31]	Xu Z, Zhao C, Wang Z, et al.Interleukin-33 levels are elevated in chronic allograft dysfunction of kidney transplant recipients and promotes epithelial to mesenchymal transition of human kidney (HK-2) cells[J]. Gene, 2018, 644: 113-121.
[32]	Liu X, Liu K, Gui Z, et al.IL-33 gene polymorphisms correlate with renal allograft fibrosis[J]. J Immunol Res, 2021: 8029180.
[33]	Liang H, Xu F, Wen XJ, et al.IL-33 signaling drives renal fibrosis post-ischemia reperfusion[J]. Eur J Pharmacol, 2017, 812: 18-27.

IL-33/ST2信号通路在肾脏疾病中作用机制的研究进展

Research progress on the mechanism of IL-33/ST2 signaling pathway in kidney diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 33

相关文章 15

编辑推荐

Metrics

本文评价

[1]	漆文霞, 王钢, 闫彦峰, 田杰祥, 刘海龙, 魏勇, 王嘉. 滋阴润燥丸对干燥综合征模型小鼠颌下腺炎症及功能作用研究[J]. 中国临床药理学与治疗学, 2026, 31(2): 196-203.
[2]	虞旭友, 张启祥, 刘嘉莉, 王广基, 周芳. 间充质干细胞衍生细胞外囊泡用于炎症性肠病的研究进展[J]. 中国临床药理学与治疗学, 2026, 31(2): 247-256.
[3]	沈小平, 吴东, 于丽丽, 吴斌. 糖酵解-乳酸化修饰在哮喘中的潜在作用与治疗展望[J]. 中国临床药理学与治疗学, 2026, 31(1): 96-106.
[4]	文一如, 杨金拉姆, 美嘎, 李娜, 录亚鹏, 张琰, 刘婕婷. 巨噬细胞极化与肠道菌群及其代谢产物在器官损伤中相关研究进展[J]. 中国临床药理学与治疗学, 2026, 31(1): 125-132.
[5]	吕程果, 吴采倩, 米芊睿, 张国婧, 李玲, 叶啟发. Apelin：慢性肾脏疾病防治的新靶点[J]. 中国临床药理学与治疗学, 2025, 30(9): 1243-1252.
[6]	靳丽丽, 郄涛, 李立琴. 司美格鲁肽通过调控AMPK/mTOR/ULK1通路介导的自噬减轻缺氧/复氧AC16人心肌细胞炎症损伤[J]. 中国临床药理学与治疗学, 2025, 30(8): 1058-1066.
[7]	黄运超, 王益琼, 张婷, 张鋆, 李兰, 张玲. 西红花酸通过抗炎促血管新生改善糖尿病下肢缺血作用研究[J]. 中国临床药理学与治疗学, 2025, 30(7): 899-906.
[8]	苏红, 程骞, 王雅轩, 戴重阳, 赵富邦, 蒲小燕. 高海拔低氧暴露后中性粒细胞胞外诱捕网释放与高原肺水肿相关微循环障碍的动态变化研究[J]. 中国临床药理学与治疗学, 2025, 30(6): 732-740.
[9]	高子恬, 陈彧, 贺海东, 唐余燕. 短链脂肪酸调控NLRP3炎症小体通路在慢性肾脏病中的作用及中药干预的研究进展[J]. 中国临床药理学与治疗学, 2025, 30(6): 812-819.
[10]	许婷婷, 汪万杰, 鲍静, 夏瑞祥. NLRC4介导的炎症小体通路与多发性骨髓瘤的关系及治疗前景[J]. 中国临床药理学与治疗学, 2025, 30(4): 501-508.
[11]	崔涵雨, 胡长平. 巨噬细胞极化与心血管疾病研究进展[J]. 中国临床药理学与治疗学, 2025, 30(4): 548-555.
[12]	李晓楠, 李阳, 许张茜, 康淑珍, 孔丽, 张志平. 靶向递送策略在炎症性肺部疾病中的研究进展[J]. 中国临床药理学与治疗学, 2025, 30(3): 313-324.
[13]	周莎莎, 程雪清, 彭冬冬, 王小青, 扶丽君, 肖文喜, 张国民. 清热消炎宁抗甲型流感H3N2病毒的药效及作用机制研究[J]. 中国临床药理学与治疗学, 2025, 30(3): 347-354.
[14]	刘静, 侯凯, 张丽. 紫铆因改善非酒精性脂肪性肝炎及作用机制研究[J]. 中国临床药理学与治疗学, 2025, 30(3): 355-365.
[15]	董家珊, 陈嘉睿, 曾大勇, 刘亦伟, 许建文, 林荣芳. 炎症性肠病患者GST基因多态性与硫唑嘌呤活性代谢物6-TGN浓度水平相关性研究[J]. 中国临床药理学与治疗学, 2025, 30(10): 1383-1390.